Critical Review: Oxford BioMedica (OTCMKTS:OXBDF) versus SUNDANCE ENERGY/S (OTCMKTS:SNDE)
Oxford BioMedica (OTCMKTS:OXBDF) and SUNDANCE ENERGY/S (NASDAQ:SNDE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
Valuation & Earnings
This table compares Oxford BioMedica and SUNDANCE ENERGY/S’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Oxford BioMedica||$89.14 million||6.45||$9.85 million||$0.15||58.33|
|SUNDANCE ENERGY/S||$66.61 million||17.44||N/A||N/A||N/A|
Insider and Institutional Ownership
0.0% of SUNDANCE ENERGY/S shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Oxford BioMedica and SUNDANCE ENERGY/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and price targets for Oxford BioMedica and SUNDANCE ENERGY/S, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Oxford BioMedica presently has a consensus price target of $14.50, suggesting a potential upside of 65.71%. SUNDANCE ENERGY/S has a consensus price target of $8.25, suggesting a potential upside of 388.17%. Given SUNDANCE ENERGY/S’s higher possible upside, analysts plainly believe SUNDANCE ENERGY/S is more favorable than Oxford BioMedica.
Risk & Volatility
Oxford BioMedica has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, SUNDANCE ENERGY/S has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500.
SUNDANCE ENERGY/S beats Oxford BioMedica on 6 of the 7 factors compared between the two stocks.
Oxford BioMedica Company Profile
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development include OXB-102 that is in Phase I/IIa study preparation for the treatment of Parkinson's disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; and OXB-302, a gene-based cancer immunotherapy product that has completed pre-clinical development for use in the treatment of a range of cancers, as well as OXB-201 that has completed Phase I trial for the treatment of wet age-related macular degeneration and diabetic retinopathy. It is also developing gene-based therapies, such as SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, which is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Immune Design, and Microsoft. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
SUNDANCE ENERGY/S Company Profile
Sundance Energy Australia Limited operates as an onshore oil and gas company in the United States. The company explores for, develops, and produces oil and natural gas. Its exploration and development activities are focused on the Eagle Ford project in the South-Texas-Gulf Coast Basin. Sundance Energy Australia Limited was incorporated in 2004 and is based in Wayville, Australia.
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.